All Industries

Top Drug Discovery Companies

241 Drug Discovery companies, sorted by total funding raised.

Frontier Medicines

Clinical-stage precision-medicine biotech using chemoproteomics and AI to discover covalent small...

San Francisco, United States51–200Biotech, Drug Discovery
Extension Round·$255.5M·Jun 2024
Vir BiotechnologyIPO

Clinical-stage biotech developing antibody- and T-cell engager-based therapeutics for infectious ...

San Francisco, United States201–500Biotech, Drug Discovery
Growth Equity·$250.0M·Oct 2024
InventisBioIPO

Clinical-stage biopharmaceutical company developing small-molecule therapies for oncology, autoim...

Shanghai, China11–50Biotech, Life Sciences
Series D·$247.0M·Sep 2020
Seismic Therapeutic

Clinical-stage immunology biotech using machine learning to design biologic therapeutics for auto...

Cambridge, United States51–200Biotech, Drug Discovery
Extension Round·$247.0M·Jul 2025
Agios PharmaceuticalsIPO

Commercial-stage biopharmaceutical company developing therapies for rare hematologic diseases by ...

Cambridge, United States501–1000Biotech, Drug Discovery
Series C·$241.0M·Nov 2011
Engrail Therapeutics

A clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience.

San Diego, United States11–50Biotech, Drug Discovery
Series B·$221.0M·Mar 2024
DP Technology

Develops AI-for-Science platforms and tools to accelerate scientific discovery for researchers an...

Beijing, China201–500Computational Biology, Drug Discovery
Series C·$213.7M·Dec 2025
FibroGenIPO

Develops novel therapeutics in oncology and anemia, advancing antibody-drug conjugates and HIF-PH...

San Francisco, United States11–50Biotech, Life Sciences
Series F·$211.5M·Nov 2014
Chai Discovery

Chai Discovery builds frontier AI to predict and reprogram interactions between biochemical molec...

San Francisco, United States11–50Artificial Intelligence, Biotech
Venture Round·$200.0M·Dec 2025
Scipher Medicine

Precision immunology company using AI and clinico-genomic data to match autoimmune patients with ...

Boston, United States51–200Artificial Intelligence, Drug Discovery
Series D·$197.8M·Jul 2024
Plexium

Next-generation targeted protein degradation biotech company developing monovalent degraders for ...

San Diego, United States51–200Biotech, Drug Discovery
Venture Round·$197.1M·Aug 2025
SchrödingerIPO

Physics-based computational platform for molecular design that helps pharmaceutical, biotechnolog...

New York, United States501–1000Artificial Intelligence, Biotech
Series E·$195.0M·May 2019
Aera Therapeutics

Biotechnology company developing next-generation genetic medicines using a proprietary protein na...

Boston, United States51–200Biotech, Drug Discovery
Series A·$193.0M·Feb 2023
Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe...

Boston, United States11–50Biopharmaceutical, CNS
Venture Round·$192.4M·Jun 2023
SpliceBio

SpliceBio is a biotechnology company exploiting Protein Splicing to develop next generation gene ...

Barcelona, Spain11–50Biotech, Drug Discovery
Series B·$192.0M·Jun 2025
Hexagon Bio

Biopharmaceutical company using genomics, computation, and synthetic biology to discover microbia...

Menlo Park, United States51–200Biotech, Drug Discovery
Series C·$185.3M·Feb 2023
Terray Therapeutics

AI-native biotech company using ultra-miniaturized chemistry hardware and machine learning for sm...

Monrovia, United States51–200Artificial Intelligence, Biotech
Series B·$180.0M·Oct 2024
Verge Genomics

We use human data and AI to develop better drugs faster.

South San Francisco11–50Biotech, Drug Discovery
Corporate Round·$176.1M·Sep 2023
Alentis Therapeutics

Clinical-stage biotech developing anti‑Claudin-1 ADCs and antibodies for cancer and organ fibrosis.

Basel, Switzerland51–200Biotech, Drug Discovery
Series C·$172.0M·Apr 2023
Tata 1mgAcquired

Indian online pharmacy and healthcare platform offering medicines, lab tests, doctor consultation...

Gurgaon, India1001–5000E-Commerce, Healthcare
Series D·$156.1M·Sep 2022
Addex TherapeuticsIPO

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally ava...

Plan-les-Ouates, Switzerland11–50Biopharmaceutical, Biotech
Extension Round·$155.9M·Aug 2022
EpizymeIPO

Biopharmaceutical company that is creating innovative drugs for major diseases based on important...

Cambridge, United States201–500Biotech, Drug Discovery
Growth Equity·$154.0M·Nov 2019
Sagimet BiosciencesIPO

A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat impo...

San Mateo, United States11–50Biotech, Drug Discovery
Growth Equity·$153.5M·Feb 2021
ElektrofiAcquired

Develops Hypercon hyper-concentrated microparticle formulations to enable subcutaneous delivery o...

Boston, United States51–200Life Sciences, Biotech
Series C·$152.3M·Oct 2024
Ideaya BiosciencesIPO

Clinical-stage precision medicine oncology company developing targeted therapeutics using molecul...

South San Francisco, United States201–500Biotech, Drug Discovery
Series A·$140.0M·Jul 2024